The current PE ratio of NGNE cannot be calculated, as the latest EPS of -$4.35 is negative.
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | N/A | N/A | $22.86 | -$4.28 |
2023 | N/A | N/A | $19.38 | -$117.28 |
2022 | N/A | N/A | $10.18 | -$139.88 |
2021 | N/A | N/A | $96.4 | -$22 |
2020 | N/A | N/A | $282 | -$12.8 |
2019 | N/A | N/A | $246.4 | -$51.4 |
2018 | N/A | N/A | $43.2 | -$26.8 |
2017 | N/A | N/A | $235.2 | -$42.8 |
2016 | N/A | N/A | $330.2 | -$39.2 |
2015 | N/A | N/A | $249.6 | -$34.6 |
2014 | N/A | N/A | $150 | -$55 |
2013 | N/A | N/A | N/A | -$990.4 |
2012 | N/A | N/A | N/A | -$804.6 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Mar 2025 | N/A | N/A | $11.71 | -$4.35 |
Dec 2024 | N/A | N/A | $22.86 | -$4.28 |
Sep 2024 | N/A | N/A | $41.96 | -$32.9 |
Jun 2024 | N/A | N/A | $36.39 | -$64.38 |
Mar 2024 | N/A | N/A | $50.9 | -$89.97 |
Dec 2023 | N/A | N/A | $19.38 | -$117.28 |
Sep 2023 | N/A | N/A | $15.8 | -$211.55 |
Jun 2023 | N/A | N/A | $16.6 | -$183.6 |
Mar 2023 | N/A | N/A | $14 | -$162.52 |
Dec 2022 | N/A | N/A | $10.18 | -$139.88 |
Sep 2022 | N/A | N/A | $12.8 | -$21.32 |
Jun 2022 | N/A | N/A | $20.6 | -$22.2 |
Mar 2022 | N/A | N/A | $37.6 | -$22 |
Dec 2021 | N/A | N/A | $96.4 | -$22 |
Sep 2021 | N/A | N/A | $144.6 | -$21 |
Stock name | PE ratio | Market cap |
---|---|---|
OLMA Olema Pharmaceuticals Inc | N/A | $298.32M |
OMER Omeros Corp | N/A | $210.93M |
VIVS VivoSim Labs Inc. | N/A | $2.68M |
ORIC Oric Pharmaceuticals Inc | N/A | $670.36M |
ORMP Oramed Pharmaceuticals Inc | N/A | $88.24M |
NGNE Neurogene Inc | N/A | $345.43M |
The current price to earnings ratio of NGNE cannot be determined, as its EPS of -$4.35 is negative.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.